⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
APRE News
Aprea Therapeutics, Inc. Common stock
Aprea Therapeutics to Present at October Conferences
globenewswire.com
APRE
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
globenewswire.com
APRE
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com
APRE
Form 8-K
sec.gov
APRE
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
globenewswire.com
APRE
Form 8-K
sec.gov
APRE
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
globenewswire.com
APRE
Lipocine Appoints Michael J. Grissinger to Board of Directors
prnewswire.com
ACET
APRE
LPCN
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
globenewswire.com
APRE
Form 8-K
sec.gov
APRE